The inability to accept responsibility is a very undesirable trait in anyone who an employer might hire. It can be an indication of a personality disorder, particularly those in Cluster B. But, even if it’s only due to anxiety, depression, or a general personality trait, it’s a mistake to hire. They likely will blame others, disrupt team dynamics, hinder problem-solving, take extra time to manage, and more. This is why interviewers ask about a candidate’s weakness, a time they received criticism, what their biggest mistake was, etc.
In just 3 years, down rounds went from 2-4% in 2021 to:
• Series Seed: 24%
• Series A: 20%
• Series B: 21%
• Series C: 29%*
• Series D+: 37%
*Series C saw the most dramatic leap (7.8% → 29.3% in two years).
Data: @CooleyLLP Q4 2024 Venture Financing Report
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and more.
#biopharma#immunology#biospace
https://t.co/IzAUcL9bhC
Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, announced Thursday it's shutting down from lack of investor interest.
https://t.co/WpNrb0Fk2X
BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to back-to-back series from obesity-focused Metsera that totaled more than $500M in a space that has garnered more than a fivefold increase in VC dollars this year.
https://t.co/QIjJvIkvFO
Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine pipelines.
#biopharma#JPM2025#obesity#vaccines#biospace
https://t.co/BdE148azJ0
On the heels of an FDA approval for its monoclonal antibody Bizengri, Merus will generate three novel cancer-targeting antibodies that it will pass over to Biohaven to link into antibody drug-conjugates.
#FDA#pharma#biospace
https://t.co/Euzrnm6HrW
BREAKING: J&J is acquiring Intra-Cellular Therapies for $14.6 billion in the biggest biotech M&A transaction since 2023.
https://t.co/1WUlLMPBed
Fewer job vacancies are being filled by hiring the unemployed and more are being filled by “poaching” workers from other firms. Go to the FRED Blog for @BLS_gov data and recent research that explains the new shape of the labor market https://t.co/u9SWJ8me72
Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 deals in 2023.
#venturecapital#biopharma#biospace
https://t.co/CrkfUHZDJ3
Edgewise Therapeutics $EWTX Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) - https://t.co/s1iYTSp8AM